Is retatrutide FDA approved?
No. Retatrutide (LY3437943) is an investigational drug. It has not received marketing approval from the US Food and Drug Administration, the European Medicines Agency or any other regulator as of September 2026.
It cannot be prescribed, it cannot be dispensed by a pharmacy, and it cannot be compounded, because compounding pharmacies may only use approved drugs or substances on the FDA's bulk substance lists, and retatrutide is on neither[1].
What has changed in 2026 is the amount of phase 3 evidence and the existence of a lawful pre-approval route. The three master-protocol obesity trials of the TRIUMPH program are listed as completed on ClinicalTrials.gov: TRIUMPH-1 in obesity without diabetes, 2 335 participants, completed 30 April 2026[2]; TRIUMPH-2 in obesity with type 2 diabetes, 1 152 participants, completed 16 June 2026[3]; TRIUMPH-3 in severe obesity with cardiovascular disease, 1 946 participants, completed 14 May 2026[4].
The program design, which nests obstructive sleep apnoea and knee osteoarthritis studies inside the weight-management trials and planned over 5 800 participants, was published in Diabetes, Obesity and Metabolism[5].
Completion of a trial is not approval. Lilly has to file a New Drug Application with the full data, and the FDA review of a standard application takes ten months from filing, six under priority review. No filing date has been published in a peer-reviewed or regulatory source that we can cite, so this site does not give a predicted approval date.
Key numbers
Figure 2
What the published trials show
The evidence base runs from a phase 1b multiple-ascending-dose trial in 72 people with type 2 diabetes, run between December 2019 and December 2020[6], through the phase 2 trials of 2023, to the first published phase 3 in 2026.
In the phase 2 obesity trial, 338 adults were randomised to placebo or retatrutide at 1, 4, 8 or 12 mg once weekly for 48 weeks. Mean body weight change at 48 weeks was -8.7 % at 1 mg, -17.1 % at 4 mg, -22.8 % at 8 mg and -24.2 % at 12 mg, against -2.1 % with placebo. Adverse events were mostly gastrointestinal, dose-related and mild to moderate, and a lower 2 mg starting dose partially mitigated them[7].
A liver-fat substudy in 98 participants with metabolic dysfunction-associated steatotic liver disease found relative reductions in liver fat at 24 weeks of -81.4 % at 8 mg and -82.4 % at 12 mg, with 86 % of participants on 12 mg reaching normal liver fat[8].
In the phase 3 TRANSCEND-T2D-1 trial, 537 adults with type 2 diabetes inadequately controlled by diet and exercise received retatrutide 4, 9 or 12 mg or placebo for 40 weeks. HbA1c fell by 1.69, 1.86 and 1.94 percentage points against 0.81 with placebo, and body weight by 11.5 %, 13.9 % and 15.3 % against 2.6 %. Discontinuation for adverse events was 2 % to 5 % with retatrutide[9].
These are trial results in monitored participants on GMP material; they say nothing about what a research vial does in anyone. Further reading on the adverse events reported across these trials: Retatrutide Risk (https://retatrutiderisk.com), a sister site built on the same publications.
In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.
Expanded access: the one pre-approval route for patients
In June 2026 Lilly registered a single-patient expanded access program for retatrutide, NCT07629401, listed as available. The criteria are narrow: age 18 or older, refractory obesity with a BMI of 35 kg/m² or more despite the highest tolerated dose of an approved weight-management therapy, two or more serious or life-threatening obesity-related complications under standard care, inability to join an ongoing retatrutide trial, and a documented discussion of all standard options including bariatric surgery. Requests come from the treating physician, not the patient, through the Lilly Answers Center[10].
The program became public knowledge after a BMJ report in August 2026 on Lilly's decision to open compassionate use in the United States[11], and it is the only lawful way, outside a trial, for a person to receive retatrutide before approval.
The FDA's expanded access framework is the legal basis[12]. It is not a route for people who simply want the drug; it is a route for people whose physicians can document that nothing approved has worked and no trial is available.
Everything else that reaches patients before approval, telehealth offers, compounded versions, online listings for weight loss, is either not retatrutide or not lawful as a medicine. The legal status article goes through each claim in turn, and how to get retatrutide describes the trial route in practice.
What an approval would change, and what it would not
Approval would create a prescription medicine with a brand name, a fixed dose ladder, a label, a price and a pharmacy supply chain. It would also change the legal position of everything else.
Once an FDA-approved product exists, an unapproved copy of it is more clearly an unapproved new drug, and the research-chemical frame becomes harder to defend for a molecule that is, at that point, a marketed medicine. Research vendors of semaglutide and tirzepatide have lived with that tension since those drugs were approved.
What approval would not change is anything about the vials sold as research chemicals today. A lot tested in 2026 is described by its certificate, not by a future label.
The content variation found in the Australian analysis, 51 % to 190 % of label[13], is a property of that supply chain, and an approval elsewhere does not fix it. Anyone sourcing the research chemical now should be reading the COA rather than the news.
The trials are done. Approval is a filing and a review away. Until it happens, the honest description of retatrutide is the one this site uses on every page: an investigational compound, not approved by the FDA or the EMA. That is also the frame in which the buying guide reads every listing.
Questions readers ask
When will retatrutide be FDA approved?
No date has been published in a regulatory or peer-reviewed source. The phase 3 obesity trials completed in April to June 2026; a New Drug Application must be filed and reviewed, which takes six to ten months from filing. This site does not predict a date.
Is retatrutide approved anywhere in the world?
No. As of September 2026 it is not approved by the FDA, the EMA or any other regulator that we can cite.
What is retatrutide expanded access?
A pre-approval, single-patient program registered by Lilly as NCT07629401 in June 2026, for adults with a BMI of 35 or more, two serious obesity-related complications, no trial option and a physician who requests it. Availability depends on supply and eligibility.
How much weight loss did retatrutide show in trials?
In the phase 2 obesity trial, mean body weight change at 48 weeks was -24.2 % at 12 mg and -22.8 % at 8 mg, against -2.1 % with placebo (DOI 10.1056/NEJMoa2301972). Phase 3 TRANSCEND-T2D-1 showed -15.3 % at 12 mg over 40 weeks in type 2 diabetes (DOI 10.1016/S0140-6736(26)00967-0).
